Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II multi-asset umbrella trial of ANOC-001 for the treatment of patients with advanced pancreatic cancer

Next Previous
X
Search
Trial Profile

A Phase I/II multi-asset umbrella trial of ANOC-001 for the treatment of patients with advanced pancreatic cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANOC 001 (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms VIDAR-1

    • Most Recent Events

    • 03 Dec 2024 New trial record
    • 26 Nov 2024 According to an Anocca media release, company announced the submission of its first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase I/II multi-asset umbrella trial, VIDAR-1.Subject to approval, company aims to initiate the study in Q2, 2025.
    • 26 Nov 2024 According to an Anocca media release, Phase I is planned for eight sites in four countries with additional countries and sites in phase II. Patients will be eligible to enroll if they have a HLA and KRAS mutation matching an available product.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top